ThermoGenesis (THMO) Scheduled to Post Earnings on Monday

ThermoGenesis (NASDAQ:THMO) will be posting its quarterly earnings results after the market closes on Monday, November 13th. Analysts expect ThermoGenesis to post earnings of ($0.21) per share for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

ThermoGenesis (NASDAQ:THMO) last posted its quarterly earnings results on Thursday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.01 by ($0.92). The business had revenue of $2.27 million during the quarter, compared to analyst estimates of $4.57 million. ThermoGenesis had a negative return on equity of 365.72% and a negative net margin of 145.48%. On average, analysts expect ThermoGenesis to post $-3 EPS for the current fiscal year and $0 EPS for the next fiscal year.

ThermoGenesis Stock Down 1.9 %

Shares of ThermoGenesis stock opened at $1.03 on Friday. ThermoGenesis has a 12-month low of $0.90 and a 12-month high of $6.75. The stock’s fifty day moving average is $1.15 and its 200-day moving average is $1.34.

Institutional Investors Weigh In On ThermoGenesis

Hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC acquired a new stake in ThermoGenesis during the second quarter worth about $52,000. Renaissance Technologies LLC lifted its holdings in shares of ThermoGenesis by 306.3% during the 3rd quarter. Renaissance Technologies LLC now owns 156,000 shares of the company’s stock worth $39,000 after acquiring an additional 117,600 shares during the period. Armistice Capital LLC acquired a new stake in shares of ThermoGenesis during the 1st quarter valued at about $328,000. Two Sigma Investments LP acquired a new position in ThermoGenesis in the first quarter worth about $40,000. Finally, Jane Street Group LLC bought a new position in ThermoGenesis during the first quarter worth about $37,000. 4.71% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright restated a “buy” rating and issued a $5.00 target price on shares of ThermoGenesis in a report on Friday, August 11th.

About ThermoGenesis

ThermoGenesis Holdings, Inc develops, commercializes, and markets a range of automated technologies for chimeric antigen receptor (CAR-T) and other cell-based therapies. It markets a suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market.